|
🐜
|
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
17 auth.
F. Martins,
Latifyan Sofiya,
G. Sykiotis,
F. Lamine,
M. Maillard,
M. Fraga,
K. Shabafrouz,
C. Ribi,
A. Cairoli,
Y. Guex-Crosier,
...
T. Kuntzer,
O. Michielin,
S. Peters,
G. Coukos,
F. Spertini,
John A Thompson,
M. Obeid
|
10 |
2019 |
10
🐜
|
|
🐜
|
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease
17 auth.
C. Gabay,
B. Fautrel,
J. Rech,
F. Spertini,
E. Feist,
I. Kötter,
E. Hachulla,
J. Morel,
T. Schaeverbeke,
M. Hamidou,
...
T. Martin,
B. Hellmich,
P. Lamprecht,
H. Schulze-Koops,
D. Courvoisier,
A. Sleight,
E. Schiffrin
|
7 |
2017 |
7
🐜
|
|
🐜
|
Research needs in allergy: an EAACI position paper, in collaboration with EFA
136 auth.
N. Papadopoulos,
I. Agache,
S. Bavbek,
B. Bilò,
F. Braido,
V. Cardona,
A. Custovic,
Jan deMonchy,
P. Demoly,
P. Eigenmann,
J. Gayraud,
C. Grattan,
E. Heffler,
P. Hellings,
M. Jutel,
...
E. Knol,
J. Lötvall,
A. Muraro,
L. Poulsen,
G. Roberts,
P. Schmid‐Grendelmeier,
C. Skevaki,
M. Triggiani,
R. Vanree,
T. Werfel,
B. Flood,
S. Palkonen,
R. Savli,
P. Allegri,
I. Annesi-Maesano,
F. Annunziato,
D. Antolín-Amérigo,
C. Apfelbacher,
M. Blanca,
E. Bogacka,
P. Bonadonna,
M. Bonini,
O. Boyman,
K. Brockow,
P. Burney,
J. Buters,
I. Būtienė,
M. Calderón,
L. Cardell,
J. Caubet,
S. Çelenk,
E. Cichocka-Jarosz,
C. Cingi,
M. Couto,
N. deJong,
S. D. Del Giacco,
N. Douladiris,
F. Fassio,
J. Fauquert,
Javier Fernández,
M. F. Rivas,
M. Ferrer,
Carsten Flohr,
J. Gardner,
J. Genuneit,
P. Gevaert,
Anna Groblewska,
E. Hamelmann,
H. Hoffmann,
K. Hoffmann‐Sommergruber,
L. Hovhannisyan,
V. Hox,
F. Jahnsen,
Ö. Kalaycı,
A. F. Kalpaklioglu,
J. Kleine‐Tebbe,
G. Konstantinou,
M. Kurowski,
S. Lau,
R. Lauener,
A. Lauerma,
K. Logan,
A. Magnan,
J. Makowska,
Heidi Makrinioti,
Paraskevi Mangina,
F. Manole,
A. Mari,
A. Mazon,
C. Mills,
E. Mingomataj,
B. Niggemann,
G. Nilsson,
M. Ollert,
L. O’Mahony,
S. O’Neil,
G. Pala,
A. Papi,
G. Passalacqua,
M. Perkin,
O. Pfaar,
C. Pitsios,
S. Quirce,
U. Raap,
M. Raulf‐Heimsoth,
C. Rhyner,
P. Robson-Ansley,
R. Alves,
Ž. Roje,
C. Rondón,
O. Rudzevičienė,
F. Ruëff,
M. Rukhadze,
G. Rumi,
C. Saçkesen,
Alexandra F Santos,
A. Santucci,
C. Scharf,
C. Schmidt‐Weber,
B. Schnyder,
J. Schwarze,
G. Senna,
S. Sergejeva,
S. Seys,
A. Siracusa,
I. Skypala,
M. Sokolowska,
F. Spertini,
R. Spiewak,
A. Sprikkelman,
G. Sturm,
I. Swoboda,
I. Terreehorst,
E. Toskala,
C. Traidl‐Hoffmann,
C. Venter,
B. Vlieg‐Boerstra,
Paul Whitacker,
M. Worm,
P. Xepapadaki,
C. Akdis
|
7 |
2012 |
7
🐜
|
|
🐢
|
Phase I Malaria Vaccine Trial with a Long Synthetic Peptide Derived from the Merozoite Surface Protein 3 Antigen
8 auth.
R. Audran,
M. Cachat,
Floriana Lurati,
S. Soe,
O. Leroy,
G. Corradin,
...
P. Druilhe,
F. Spertini
|
7 |
2005 |
7
🐢
|
|
🐜
|
Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.
12 auth.
B. Lauwerys,
E. Hachulla,
F. Spertini,
E. Lazaro,
C. Jorgensen,
X. Mariette,
...
E. Haelterman,
G. Grouard-Vogel,
B. Fanget,
O. Dhellin,
P. Vandepapelière,
F. Houssiau
|
7 |
2013 |
7
🐜
|
|
🐬
|
CXCR3 Internalization Following T Cell-Endothelial Cell Contact: Preferential Role of IFN-Inducible T Cell α Chemoattractant (CXCL11)1
A. Sauty,
R. Colvin,
L. Wagner,
Sophie Rochat,
F. Spertini,
A. Luster
|
7 |
2001 |
7
🐬
|
|
🐜
|
A synthetic malaria vaccine elicits a potent CD8+ and CD4+ T lymphocyte immune response in humans. Implications for vaccination strategies
8 auth.
J. López,
Christophe Weilenman,
R. Audran,
M. Roggero,
A. Bonelo,
J. Tiercy,
...
F. Spertini,
G. Corradin
|
7 |
2001 |
7
🐜
|
|
🐜
|
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
12 auth.
F. Martins,
G. Sykiotis,
M. Maillard,
M. Fraga,
C. Ribi,
T. Kuntzer,
...
O. Michielin,
S. Peters,
G. Coukos,
F. Spertini,
John A Thompson,
M. Obeid
|
7 |
2019 |
7
🐜
|
|
🦁
|
Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.
16 auth.
F. Spertini,
R. Audran,
R. Chakour,
O. Karoui,
Viviane Steiner-Monard,
A. Thierry,
Carole Mayor,
N. Rettby,
K. Jaton,
Laure Vallotton,
...
C. Lazor-Blanchet,
J. Doce,
E. Puentes,
D. Marinova,
N. Aguiló,
Carlos Martín
|
7 |
2015 |
7
🦁
|
|
🐢
|
Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial.
8 auth.
J. Fellrath,
A. Kettner,
N. Dufour,
C. Frigerio,
D. Schneeberger,
A. Leimgruber,
...
G. Corradin,
F. Spertini
|
7 |
2003 |
7
🐢
|
|
🐬
|
Targeting of Secretory IgA to Peyer’s Patch Dendritic and T Cells after Transport by Intestinal M Cells1
Jacques Rey,
N. Garin,
F. Spertini,
B. Corthésy
|
7 |
2004 |
7
🐬
|
